Edwards Lifesciences Corp header image

Edwards Lifesciences Corp

EW

Equity

ISIN null / Valor 1065343

New York Stock Exchange, Inc (2025-11-21)
USD 85.13+1.24%

Edwards Lifesciences Corp
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Edwards Lifesciences Corp is a medical technology company specializing in the development and commercialization of heart valve therapies and hemodynamic monitoring solutions.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (21.10.2025):

Edwards Lifesciences Corp reported strong financial results for the fourth quarter and full year ended December 31, 2024. The company achieved significant sales growth across all product groups, driven by robust performances in TAVR and TMTT segments. Edwards maintained a solid financial position with optimistic guidance for 2025, highlighting continued innovation and expansion in structural heart therapies.

Revenue Growth

Q4 sales increased by 9% to $1.39 billion, surpassing expectations with strong performance across all product lines. For the full year 2024, global sales reached $4.1 billion, marking a 6% year-over-year growth.

TAVR Performance

Transcatheter Aortic Valve Replacement (TAVR) sales grew by 6% in Q4 to $1.04 billion, or 5% on a constant currency basis. The U.S. SAPIEN 3 Ultra RESILIA platform continued to lead the market, while international sales benefited from the launch of SAPIEN 3 Ultra RESILIA in Europe.

TMTT Growth

Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a remarkable 88% increase in Q4 sales to $105 million, contributing significantly to the company’s overall growth. Full-year sales reached $352 million, up 78% year-over-year, driven by the PASCAL repair system and EVOQUE tricuspid replacement system.

Earnings Per Share

For Q4, Edwards reported an EPS of $0.581 and an adjusted EPS of $0.59, reflecting strong top-line performance. The company maintained its full-year 2025 adjusted EPS guidance of $2.40 to $2.50.

Clinical Trials and Innovations

Edwards presented results from the EARLY TAVR and TRISCEND II clinical trials, showcasing groundbreaking advancements in structural heart treatments. The EARLY TAVR trial, the largest of its kind, is expected to support FDA approval for treating asymptomatic severe aortic stenosis patients by mid-year.

Financial Outlook

The company reiterated its 2025 sales growth guidance of 8% to 10% on a constant currency basis and anticipates continued expansion of its structural heart therapy portfolio beyond 2026. Edwards expects total sales for Q1 2025 to be between $1.35 and $1.43 billion, with an adjusted EPS of $0.58 to $0.64.

CEO’s Statement

Bernard Zovighian, CEO of Edwards Lifesciences, emphasized the company's strong position at the end of 2024 and expressed optimism about future growth drivers, including innovations in TAVR, Mitral and Tricuspid therapies, and emerging opportunities in Structural Heart Failure and Aortic Regurgitation.

Summarized from source with an LLMView Source

Key figures

21.0%1Y
14.9%3Y
0.71%5Y

Performance

24.6%1Y
34.5%3Y
34.0%5Y

Volatility

Market cap

49401 M

Market cap (USD)

Daily traded volume (Shares)

4,848,919

Daily traded volume (Shares)

1 day high/low

75.02 / 74.08

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20
Getinge AB
Getinge AB Getinge AB Valor: 84926
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%SEK 207.60